AJD: none. JWB: none. KT: none. MP: none. LT: none. MB: none. EB: none. DHS: Consultant: Gyroscope, Roche, Alcon, BVI; Research funds: Alcon, Bayer, DORC, Gyrsocope, Boehringer-Ingelheim. CW: Dr. Wykoff reported consulting for 4DMT, AbbVie, Adverum, Alcon, Alimera, Alkeus, Annexon, Apellis, Aviceda, Bayer, Biocryst, Boehringer Ingelheim, Clearside, EyeBiotech, EyePoint, Genentech, InGel, Janssen, Kiora, KodiakMerck, Neurotech, Novartis, Ocuphire, ONL, Opthea, Osanni, Panther, Perceive Bio, Ray, Regeneron, RegenXBio, Sanofi, Santen, Stealth, Valo, Zeiss. VC: Dr. Chaudhary reports acting as an advisory board member, grants and other from Novartis; acting as an advisory board member, grants and other from Bayer; acting as an advisory board member and grants from Roche; acting as an advisory board member for Alcon; acting as an advisory board member for Apellis; and acting as an advisory board member for Boehringer Ingelheim outside the submitted work. VC is also a current member of the Eye editorial board.